HA22 is licensed to Medimmune and been given the name Moxetumomab pasudotox. It is being tested in patients with chemo-resistant hairy cell leukemia (HCL) in adults and acute lymphoblastic leukemia in children. The HCL trial is a phase 3 trial to gain FDA approval for the drug. In ALL a phase 1 trial has been completed in which there was about a 30% response rate in children with refractory disease. A phase 2 trial has now been initiated. For mesothelioma therapy we have been testing immunotoxin SS1P in combination with Pentostatin and Cytoxan and observed major prolonged responses in several patients with advanced mesothelioma. We are also carrying out a phase 1 trial with a new clinically optimized de-immunized immunotoxin (RG7787) in collaboration with Roche. The trial has just opened. Trials with LMB2 targeting CD25 in Acute T Cell Leukemia have just been completed and several durable complete responses were observed in patients with refractory disease. R. Kreitman is the lead investigator in those trials.
| Chandramohan, Vidyalakshmi; Pegram, Charles N; Piao, Hailan et al. (2017) Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial. Appl Microbiol Biotechnol 101:2747-2766 |
| Hassan, Raffit; Alewine, Christine; Pastan, Ira (2016) New Life for Immunotoxin Cancer Therapy. Clin Cancer Res 22:1055-8 |
| Hassan, Raffit; Thomas, Anish; Alewine, Christine et al. (2016) Mesothelin Immunotherapy for Cancer: Ready for Prime Time? J Clin Oncol 34:4171-4179 |
| Bao, Xuhui; Pastan, Ira; Bigner, Darell D et al. (2016) EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery. Receptors Clin Investig 3: |
| Pastan, Ira; Hassan, Raffit (2014) Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 74:2907-12 |
| Sharon, Elad; Zhang, Jingli; Hollevoet, Kevin et al. (2012) Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers. Clin Chem Lab Med 50:721-5 |
| Kelly, Ronan J; Sharon, Elad; Pastan, Ira et al. (2012) Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 11:517-25 |
| Kreitman, Robert J; Tallman, Martin S; Robak, Tadeusz et al. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30:1822-8 |
| Mehta, Ankit I; Choi, Bryan D; Ajay, Divya et al. (2012) Convection enhanced delivery of macromolecules for brain tumors. Curr Drug Discov Technol 9:305-10 |
| Mehta, Ankit I; Choi, Bryan D; Raghavan, Raghu et al. (2011) Imaging of convection enhanced delivery of toxins in humans. Toxins (Basel) 3:201-6 |
Showing the most recent 10 out of 21 publications
